Low pH Inhalation Fluid for Resistant Pathogen Eradication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The rapid spread of antimicrobial-resistant pathogens, particularly ESKAPE bacteria, poses a significant threat to human health due to the lack of effective diagnostic methods and the overuse of broad-spectrum antibiotics, leading to increased mortality from respiratory infections.
Innovation Solution
A pharmaceutically acceptable therapeutic inhalation fluid with a pH between 1.5 and 2.5, composed of a fluid carrier and a pharmaceutically acceptable acid formulation, is administered via inhalation to treat or prevent respiratory infections caused by antimicrobial-resistant pathogens, including ESKAPE bacteria, using devices like nebulizers or inhalers, and can include antimicrobial peptides for enhanced efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If broad-spectrum antibiotics are used to treat respiratory infections, then the treatment coverage is improved, but antimicrobial resistance increases and diagnostic precision deteriorates
Solution Approach 1:
The patent applies local quality by delivering acid formulations directly to the site of infection in the respiratory tract through inhalation. The low pH environment is created locally at the infection site rather than systemically, providing targeted antimicrobial action while minimizing impact on beneficial microbiota elsewhere in the body. This localized approach maintains treatment effectiveness while reducing the selection pressure that drives antimicrobial resistance.
Solution Approach 2:
The patent utilizes parameter changes by employing extreme pH values (low pH 1.0-3.0 or high pH 9.0-11.0) to create a non-physiological environment that is lethal to pathogens. This drastic change in the chemical parameter (pH) provides broad-spectrum antimicrobial activity against drug-resistant organisms without relying on traditional antibiotics, thereby avoiding further resistance development.
2Measurement precision
If rapid diagnostic methods are developed to identify bacterial pathogens, then measurement precision is improved, but device complexity and manufacturing difficulty increase
Solution Approach 1:
The patent employs self-service principles by using the patient's own respiratory secretions (sputum, saliva, or nasal washings) as the diagnostic sample, eliminating the need for complex sample collection devices. The inhalation delivery system simultaneously serves both diagnostic and therapeutic functions, reducing overall device complexity while maintaining high diagnostic precision through direct analysis of respiratory pathogens.
3Reliability
If low pH inhalation therapy is administered to treat AMR pathogens, then antimicrobial efficacy is improved, but potential harm to respiratory tissues increases
Solution Approach 1:
The patent applies periodic action by administering the extreme pH inhalation therapy in controlled cycles rather than continuously. The treatment can be alternated with neutral pH periods or progressively adjusted, allowing respiratory tissues to recover between exposures. This periodic dosing strategy maintains antimicrobial efficacy against AMR pathogens while minimizing cumulative tissue damage and irritation.
Solution Approach 2:
The patent implements beforehand cushioning by pre-conditioning the respiratory tract or using buffer systems that mitigate the extreme pH effects. The formulation may include protective agents or be administered in a sequence that gradually adapts the tissue to the extreme pH environment, reducing shock and irritation while maintaining the lethal effect on pathogens.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The low pH therapeutic demonstrates significant antimicrobial activity against both drug-sensitive and drug-resistant strains of ESKAPE bacteria, reducing pathogen loads in the respiratory tract and offering a potential solution to the growing issue of antimicrobial resistance, with minimal systemic side effects and the ability to target both Gram-negative and Gram-positive bacteria.
Implementation Method 1
A method for treating a respiratory infection caused by antimicrobial-resistant pathogens... the pharmaceutically acceptable acid formulation present in the fluid carrier in an amount sufficient to provide a solution pH between 1.5 and 2.5... demonstrating significant antimicrobial activity against both drug-sensitive and drug-resistant strains of ESKAPE bacteria
Implementation Method 2
the pharmaceutically acceptable acid formulation having anti-bacterial, and/or anti-viral, and/or anti-fungal activity... reducing pathogen loads in the respiratory tract
Data Source
AI summary
A pharmaceutically acceptable therapeutic inhalation fluid that is composed of a fluid carrier and a pharmaceutically acceptable acid formulation present in the fluid carrier in an amount sufficient to provide a solution pH between 1.5 and 2.5, the pharmaceutically acceptable acid formulation having anti-bacterial, and/or anti-viral, and/or anti-fungal activity and at least one antimicrobial peptide.